Kineta to Present KVA12123 VISTA Blocking Immunotherapy Program at Antibody Engineering and Therapeutics Conference

On December 1, 2022 Kineta, Inc. ("Kineta" or the "Company"), a clinical-stage biotechnology company focused on developing next-generation immunotherapies to address cancer immune resistance, reported that the Company will present at the Antibody Engineering and Therapeutics Conference, the Antibody Society’s Annual Meeting, to be held in-person in San Diego, CA from December 4-8, 2022 (Press release, Kineta, DEC 1, 2022, View Source;utm_medium=rss&utm_campaign=kineta-to-participate-in-jmp-securities-hematology-and-oncology-summit [SID1234624652]). Thierry Guillaudeux, Ph.D., Kineta’s Chief Scientific Officer, will give an oral presentation on KVA12123 (formerly referred to as KVA12.1). KVA12123 is the Company’s VISTA blocking immunotherapy that is expected to initiate Phase 1 clinical trials in patients with advanced solid tumors in the fourth quarter of 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details:

Title: KVA12123 (formerly referred to as KVA12.1), a VISTA Blocking Immunotherapy

Presenter: Thierry Guillaudeux, Ph.D.

Date / Time: December 7, 2022, at 8:45 A.M. Pacific Time

Session Type: Oral Presentation

A copy of the presentation will be available on the Kineta website under Publications after the conference on December 7, 2022: View Source

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

On November 30, 2022 Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, reported the pricing of an underwritten public offering of 6,550,219 shares of its common stock at a public offering price of $45.80 per share (Press release, Intellia, DEC 1, 2022, View Source [SID1234624651]). Intellia also granted the underwriter a 30-day option to purchase up to an additional 982,532 shares of its common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $300 million, excluding any exercise of the underwriters’ option to purchase additional shares. All of the shares in the offering are to be sold by Intellia.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Goldman Sachs & Co. LLC is the sole underwriter for the offering. The offering is expected to close on or about December 2, 2022, subject to customary closing conditions.

The shares of common stock are being offered by Intellia pursuant to an effective shelf registration statement, including a prospectus, that was previously filed with the U.S. Securities and Exchange Commission (SEC). The final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and may be obtained, when available, from: Goldman Sachs & Co. LLC, by mail at 200 West Street, New York, NY 10282, Attention: Prospectus Department, by telephone at (866) 471-2526, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

IGM Biosciences to Present at the Bank of America Biotech SMID Cap Conference

On December 1, 2022 IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, reported that Fred Schwarzer, Chief Executive Officer, will participate in a virtual fireside chat at the Bank of America Biotech SMID Cap Conference on Thursday, December 8, 2022 at 2:45 p.m. EST (Press release, IGM Biosciences, DEC 1, 2022, View Source [SID1234624650]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the event will be available on the "Events and Presentations" page in the "Investors" section of the Company’s website at View Source A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

Herantis Pharma applies for delisting regarding the secondary listing of its shares from Nasdaq First North Growth Market Sweden

On December 1, 2022 Herantis Pharma Plc ("Herantis") developing disease modifying therapies for Parkinson’s disease, reported that it has applied for delisting of its shares from Nasdaq First North Growth Market Sweden ("Nasdaq FN GM Sweden") (Press release, Herantis Pharma, DEC 1, 2022, View Source,c3676089 [SID1234624649]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

When adopting the decision on applying for the delisting, the Board of Directors considered the development of trading since the company listed its shares on Nasdaq FN GM Sweden in 2019, noting the low level of trading volumes as well as the small number of current shareholders holding their shares through Euroclear Sweden AB. The Company has also considered the additional costs related to maintaining this secondary listing for a company of its size as well as the administrative burden of complying with the listing rules of another market in addition to its home market in Finland.

The Company wants to remind Herantis’ shareholders holding their shares through Euroclear Sweden AB that even while the listing of Herantis’ shares on Nasdaq FN GM Sweden will be discontinued, such shareholders can continue trading in Herantis’ shares on Nasdaq First North Growth Market Finland by first arranging for the cross-border settlement of their shares into the book-entry system maintained by Euroclear Finland Oy. In order to effectuate such cross-border settlement, the shareholders should contact their respective custodian or Herantis Issuing Agent Aqurat Fondkommission AB ([email protected]) for more information.

The last day of trading on Nasdaq FN GM Sweden is expected to be January 31, 2023. More information about the delisting will be provided once Nasdaq Sweden has decided on the application.

CRISPR Therapeutics to Present at the 2022 BMO Growth & ESG Conference

On December 1, 2022 CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, reported that members of its senior management team are scheduled to participate in a fireside chat at the 2022 BMO Growth & ESG Conference on Wednesday, December 7, 2022, at 1:00 p.m. ET (Press release, CRISPR Therapeutics, DEC 1, 2022, View Source [SID1234624648]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A replay of the webcast will be archived for 14 days following the presentation on the "Events & Presentations" page in the Investors section of the Company’s website at View Source